A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Clinical trial NCT06144385 · UNKNOWN

Trial details

NCT number: NCT06144385
Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Liver Carcinoma Hepatic Cell Carcinoma

Start date: 2022-03-24
Primary completion: 2024-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.